GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

GSK buys Okairos for $324 million in vaccine boost effort

GlaxoSmithKline (GSK) has announced on its website that it has acquired Okairos AG for $325 million / £215 million in cash. Okairos is a Swiss-based biotech that specialises in developing vaccine platform technologies, and GSK expect the company's technology to play an important role in its development of new prophylactic and therapeutic vaccines. The deal also includes ownership of a …